Lung

, Volume 186, Issue 6, pp 381–386

Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting β2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease

  • Woo Jin Kim
  • Yeon-Mok Oh
  • Joohon Sung
  • Tae-Hyung Kim
  • Jin Won Huh
  • Hoon Jung
  • Ji-Hyun Lee
  • Eun-Kyung Kim
  • Jin Hwa Lee
  • Sang-Min Lee
  • Sangyeub Lee
  • Seong Yong Lim
  • Tae Rim Shin
  • Ho Il Yoon
  • Sung-Youn Kwon
  • Sang Do Lee
Article

DOI: 10.1007/s00408-008-9103-9

Cite this article as:
Kim, W.J., Oh, YM., Sung, J. et al. Lung (2008) 186: 381. doi:10.1007/s00408-008-9103-9

Abstract

Recent reports suggest that β2-adrenergic receptor (ADRB2) genotypes are associated with therapeutic responses to β2 agonists in asthmatics. However, few studies have investigated therapeutic responses to β2 agonists in chronic obstructive pulmonary disease (COPD) patients. This study investigated immediate bronchodilator response and lung function responses following a 12-week treatment with a long-acting β2 agonist combined with a steroid inhaler in patients with COPD with various ADRB2 genotypes. One hundred four patients with chronic obstruction were genotyped for codon 16 and 27 polymorphisms of the ADRB2 gene. The immediate bronchodilator response to β2-agonist treatment was evaluated after inhalation of 400 μg salbutamol. In addition, long-term response was evaluated using observed change in spirometric values before and after the treatment with salmeterol (50 μg) combined with fluticasone propionate (500 μg) inhalation twice daily for 12 weeks. In terms of codon 16 variants, the immediate bronchodilator response to salbutamol was 6.4 ± 0.8% (% predicted value) in Arg/Arg patients, 4.9 ± 0.7% in Arg/Gly patients, and 5.8 ± 1.2% in Gly/Gly patients (p = 0.418). The FEV1 changes following the 12-week treatment were 7.0 ± 1.2% in Arg/Arg patients, 3.0 ± 1.5% in Arg/Gly patients, and 7.2 ± 1.2% in Gly/Gly patients (p = 0.229). Similarly, there was no difference between codon 27 variants in terms of immediate bronchodilator response or FEV1 changes after 12 weeks of treatment. We were unable to demonstrate an association between ADRB2 genotype and the effect on lung function of 12-week treatment with combined long-acting β2 agonist and glucocorticoid inhalation or on the immediate bronchodilator response to a short-acting β2 agonist in patients with COPD.

Keywords

β-agonist COPD Polymorphism 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Woo Jin Kim
    • 1
  • Yeon-Mok Oh
    • 2
  • Joohon Sung
    • 3
  • Tae-Hyung Kim
    • 4
  • Jin Won Huh
    • 5
  • Hoon Jung
    • 5
  • Ji-Hyun Lee
    • 6
  • Eun-Kyung Kim
    • 6
  • Jin Hwa Lee
    • 7
  • Sang-Min Lee
    • 8
  • Sangyeub Lee
    • 9
  • Seong Yong Lim
    • 10
  • Tae Rim Shin
    • 11
  • Ho Il Yoon
    • 12
  • Sung-Youn Kwon
    • 12
  • Sang Do Lee
    • 2
  1. 1.Department of Internal Medicine, College of MedicineKangwon National UniversityChuncheonSouth Korea
  2. 2.Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and Clinical Research Center for Chronic Obstructive Airway DiseasesAsan Medical Center, University of Ulsan College of MedicineSeoulSouth Korea
  3. 3.Department of Cancer Prevention and EpidemiologyNational Cancer CenterGoyangSouth Korea
  4. 4.Division of Pulmonology, Department of Internal MedicineHanyang University Guri Hospital, Hanyang University College of MedicineGuriSouth Korea
  5. 5.Department of Internal MedicineIlsan Paik Hospital, Inje UniversityGoyangSouth Korea
  6. 6.Division of Pulmonary and Critical Care Medicine, Department of Internal MedicineBundang CHA Hospital, College of Medicine, Pochon CHA UniversitySeongnamSouth Korea
  7. 7.Department of Internal MedicineEwha Womans University Mokdong Hospital, College of Medicine, Ewha Womans UniversitySeoulSouth Korea
  8. 8.Division of Pulmonary and Critical Care Medicine, Department of Internal MedicineClinical Research Institute, Seoul National University Hospital, Lung Institute, Medical Research Center, Seoul National University College of MedicineSeoulSouth Korea
  9. 9.Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of MedicineKorea University Anam HospitalSeoulSouth Korea
  10. 10.Division of Pulmonary and Critical Care Medicine, Department of MedicineKangbuk Samsung Hospital, Sungkyunkwan University School of MedicineSeoulSouth Korea
  11. 11.Department of Internal MedicineKangnam Sacred Heart Hospital, Hallym University College of MedicineSeoulSouth Korea
  12. 12.Respiratory Center, Seoul National University Bundang Hospital, Department of Internal Medicine, Seoul National University College of MedicineSeongnamSouth Korea

Personalised recommendations